Triggering RNA Interference by Photoreduction under Red Light Irradiation.

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Therapeutics

Background:

• RNA interference (RNAi) with small interfering RNAs (siRNAs) is a promising therapeutic strategy.
• Current red-light-activatable siRNA prodrugs utilize singlet oxygen, which is cytotoxic and produces toxic byproducts like anthraquinone.
• There is a need for safer, externally triggered siRNA activation for in vivo cancer treatment.

Purpose of the Study:

• To develop an improved red-light-activatable siRNA prodrug that bypasses singlet oxygen activation.
• To enhance the safety profile of light-activated siRNA therapeutics for cancer treatment.
• To demonstrate the red-light-induced activation of the novel siRNA prodrug in vitro and in cancer cells.

Main Methods:

• Design and synthesis of a novel siRNA prodrug featuring an azobenzene promoiety at the 5' terminus of the antisense strand.
• Red light irradiation in the presence of a Sn(IV)(pyropheophorbide a)dichloride catalyst and ascorbate as a reducing agent.
• Confirmation of prodrug activation using cell-free assays and human ovarian cancer A2780 cells.

Main Results:

• The novel azobenzene-modified siRNA prodrug is activated upon red light exposure without generating singlet oxygen.
• The activation mechanism involves reduction and cleavage of the azobenzene moiety.
• Successful red-light-induced activation was confirmed in both cell-free conditions and within human ovarian cancer cells.

Conclusions:

• This study presents a new, safer red-light-activatable siRNA prodrug for potential cancer therapy.
• The developed prodrug avoids the toxic side effects associated with singlet oxygen-mediated activation.
• This advancement offers a more selective and potentially less toxic approach to RNA interference-based cancer treatments.